MX2022015250A - Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. - Google Patents

Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.

Info

Publication number
MX2022015250A
MX2022015250A MX2022015250A MX2022015250A MX2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A MX 2022015250 A MX2022015250 A MX 2022015250A
Authority
MX
Mexico
Prior art keywords
methods
inflammatory diseases
treating inflammatory
diseases
crohn
Prior art date
Application number
MX2022015250A
Other languages
English (en)
Inventor
Annette Bettina Galler
Steven John Padula
Bojan LALOVIC
Sudha Visvanathan
Paul Scholl
Wulf Otto Boecher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022015250A publication Critical patent/MX2022015250A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere generalmente a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular, enfermedades inflamatorias, tales como la enfermedad de Crohn, que utilizan anticuerpos anti-IL-23ª.
MX2022015250A 2015-09-18 2018-03-14 Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. MX2022015250A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562220410P 2015-09-18 2015-09-18
US201562235654P 2015-10-01 2015-10-01
US201662295643P 2016-02-16 2016-02-16
US201662328863P 2016-04-28 2016-04-28
US201662335242P 2016-05-12 2016-05-12
US201662339192P 2016-05-20 2016-05-20

Publications (1)

Publication Number Publication Date
MX2022015250A true MX2022015250A (es) 2023-01-11

Family

ID=57003593

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018003174A MX2018003174A (es) 2015-09-18 2016-09-15 Metodos para tratar enfermedades inflamatorias.
MX2022015248A MX2022015248A (es) 2015-09-18 2018-03-14 Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2022015250A MX2022015250A (es) 2015-09-18 2018-03-14 Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018003174A MX2018003174A (es) 2015-09-18 2016-09-15 Metodos para tratar enfermedades inflamatorias.
MX2022015248A MX2022015248A (es) 2015-09-18 2018-03-14 Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.

Country Status (16)

Country Link
US (1) US20170081402A1 (es)
EP (1) EP3350221A1 (es)
JP (5) JP6668461B2 (es)
KR (1) KR20180053395A (es)
CN (1) CN108026168A (es)
AU (2) AU2016323152A1 (es)
BR (1) BR112018003526A2 (es)
CA (1) CA2996645A1 (es)
CL (1) CL2018000597A1 (es)
EA (1) EA201890747A1 (es)
HK (1) HK1252037A1 (es)
IL (2) IL302197A (es)
MX (3) MX2018003174A (es)
PH (1) PH12018500578A1 (es)
TW (2) TWI733695B (es)
WO (1) WO2017048901A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282382B (zh) 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3677597A1 (en) * 2016-10-14 2020-07-08 Boehringer Ingelheim International GmbH Methods of treating diseases
JP2021515770A (ja) * 2018-03-05 2021-06-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN112578123B (zh) * 2019-09-27 2022-10-25 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
MX2023007933A (es) 2021-01-06 2023-09-15 Abbvie Inc Métodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
MX2008002179A (es) * 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
ES2619845T3 (es) 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN103282382B (zh) * 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
KR102124758B1 (ko) * 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
CN105307675A (zh) * 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
JP7060806B2 (ja) * 2018-08-22 2022-04-27 富士通株式会社 情報処理装置、データ管理方法およびデータ管理プログラム
JP2020030579A (ja) * 2018-08-22 2020-02-27 信越ポリマー株式会社 Ｒｆｉｄタグ埋設体およびその製造方法

Also Published As

Publication number Publication date
JP7477492B2 (ja) 2024-05-01
JP6668461B2 (ja) 2020-03-18
MX2018003174A (es) 2018-05-17
JP2020100644A (ja) 2020-07-02
EP3350221A1 (en) 2018-07-25
US20170081402A1 (en) 2017-03-23
CL2018000597A1 (es) 2018-07-27
JP2020100643A (ja) 2020-07-02
AU2023203530A1 (en) 2023-07-06
TW201722474A (zh) 2017-07-01
JP7000476B2 (ja) 2022-02-04
TW202138008A (zh) 2021-10-16
HK1252037A1 (zh) 2019-05-10
IL257561A (en) 2018-04-30
BR112018003526A2 (pt) 2018-09-25
JP2022046624A (ja) 2022-03-23
PH12018500578A1 (en) 2018-09-10
TWI811716B (zh) 2023-08-11
JP2018527380A (ja) 2018-09-20
AU2016323152A1 (en) 2018-02-22
EA201890747A1 (ru) 2018-10-31
WO2017048901A1 (en) 2017-03-23
KR20180053395A (ko) 2018-05-21
IL302197A (en) 2023-06-01
CN108026168A (zh) 2018-05-11
JP2022088478A (ja) 2022-06-14
CA2996645A1 (en) 2017-03-23
MX2022015248A (es) 2023-01-11
TWI733695B (zh) 2021-07-21

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12018500578A1 (en) Methods of treating inflammatory diseases
ZA201905488B (en) Tigit- and light-based chimeric proteins
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
NZ738008A (en) Tigit-binding agents and uses thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
MX2022006573A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2021008663A (es) Anticuerpos mejorados contra il-6.
WO2015187521A3 (en) Anti-blys antibodies
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
MX2017006692A (es) Trastornos neurodegenerativos.
MX2019014291A (es) Metodo de tratamiento.
PH12017501872A1 (en) Methods of treating diseases
WO2017042577A8 (en) Novel therapy
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis